Adverse events of biological agents in pediatric rheumatologic diseases

References

• Sullivan KE. Pathogenesis of pediatric rheumatologic diseases. Pediatr Clin North Am. 2018;65(4):639–655. doi: 10.1016/j.pcl.2018.03.004
   PubMed Web of Science ®Google Scholar
• Breda L, Torto MD, Sanctis SD, et al. Biologics in children’s autoimmune disorders: efficacy and safety. Eur J Pediatr. 2011;170(2):157–67. doi: 10.1007/s00431-010-1238-z
   PubMed Web of Science ®Google Scholar
• Sen ES, Ramanan AV. New age of biological therapies in paediatric rheumatology. Arch Dis Child. 2014;99(7):679–85. doi: 10.1136/archdischild-2013-304396
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Massaro L, et al. Biological therapies in rheumatic diseases. Clin Ter. 2013;164(5):e413–e428. doi: 10.7417/CT.2013.1622
   PubMed Web of Science ®Google Scholar
• Huang B, Qiu T, Chen C, et al. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020;6(1):e001091. doi: 10.1136/rmdopen-2019-001091
   PubMed Web of Science ®Google Scholar
• Kurt T, Aydın F, Tekgöz N, et al. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: a single-center experience. Int J Rheum Dis. 2020;23(7):977–981.
   PubMed Web of Science ®Google Scholar
• Lucherini OM, Rigante D, Sota J, et al. Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases. Clin Exp Rheumatol. 2018;110(1):3–9.
   Google Scholar
• Jamilloux Y, Lefeuvre L, Magnotti F, et al. Familial Mediterranean fever mutations are hypermorphic mutations that specifically decrease the activation threshold of the pyrin inflammasome. Rheumatology (Oxford). 2018;57(1):100–111. doi: 10.1093/rheumatology/kex373
   PubMed Web of Science ®Google Scholar
• Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–271. doi: 10.1016/j.semarthrit.2010.11.003
   PubMed Web of Science ®Google Scholar
• Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American college of rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022;81(7):907–921. doi: 10.1136/annrheumdis-2021-221801
   PubMed Web of Science ®Google Scholar
• Onel KB, Horton DB, Lovell DJ, et al. 2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553–569. doi: 10.1002/art.42037
   PubMed Web of Science ®Google Scholar
• Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734. doi: 10.1002/acr.23870
   PubMed Web of Science ®Google Scholar
• Morishita K, Brown K, Cabral D. Pediatric vasculitis: advances in treatment. Curr Opin Rheumatol. 2015;27(5):493–9. doi: 10.1097/BOR.0000000000000203
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818. doi: 10.1136/annrheumdis-2018-213225
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2023;12:ard-2023–224762. doi: 10.1136/ard-2023-224762
   Google Scholar
• Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–340. doi: 10.1136/annrheumdis-2016-209247
   PubMed Web of Science ®Google Scholar
• Sota J, Vitale A, Insalaco A, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018;37(8):2233–2240. doi: 10.1007/s10067-018-4119-x
   PubMed Web of Science ®Google Scholar
• Klein A, Becker I, Minden K, et al. Biologic therapies in polyarticular juvenile idiopathic arthritis. ACR Open Rheumatol. 2020;2(1):37–47. doi: 10.1002/acr2.11091
   PubMedGoogle Scholar
• Cabreraa N, Legaa JC, Kassai B, et al. Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine. 2019;86(3):343–50. doi: 10.1016/j.jbspin.2018.08.003
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Tuberculosis. In: Kimberlin D, Brady M, Jackson M, Long S, editors. Red book: 2018-2021 report of the Committee on Infectious diseases. 31st ed. Elk Grove Village (IL):American Academy of Pediatrics; 2018. p. 829–853.
   Google Scholar
• International council for harmonization and good clinical practice, ICH-GCP: guideline for good clinical practice. E6(R2) 2016. EMA/CHMP/ICH/135/1955.
   Google Scholar
• Thiele F, Klein A, Windschall D, et al. Comparative risk of infections among real‑world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatol Int. 2021;41(4):751–762.
   PubMed Web of Science ®Google Scholar
• Atemnkeng Ntam V, Klein A, Horneff G. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry. Expert Opin Drug Saf. 2020;20(1):93–100. doi: 10.1080/14740338.2021.1843631
   PubMed Web of Science ®Google Scholar
• Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry. J Rheumatol. 2022;49(4):398–407. doi: 10.3899/jrheum.210563
   PubMed Web of Science ®Google Scholar
• Tarkiainen M, Tynjälä P, Vähäsalo P, et al. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. Rheumatology (Oxford). 2015;54(7):1170–1176. doi: 10.1093/rheumatology/keu457
   PubMed Web of Science ®Google Scholar
• Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German biologics in pediatric rheumatology registry. Arthritis Care Res. 2017;69(4):552–560. doi: 10.1002/acr.22961
   PubMed Web of Science ®Google Scholar
• Davies HD, Byington CL, Maldonado YA. Committee on infectious diseases. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2):e20161209. doi: 10.1542/peds.2016-1209
   PubMed Web of Science ®Google Scholar
• Toussi SS, Pan N, Walters HM, et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor- inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57(9):1318–1330.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev. 2015;14(1):1–9. doi: 10.1016/j.autrev.2014.08.008
   PubMed Web of Science ®Google Scholar
• Özlü C, Türkuçar S, Karaoğlu Asrak H, et al. Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases. Turk J Pediatr. 2021;63(6):978–85. doi: 10.24953/turkjped.2021.06.005
   PubMed Web of Science ®Google Scholar
• Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–1441. doi: 10.1007/s10067-014-2498-1
   PubMed Web of Science ®Google Scholar
• Lainka E, Baehr M, Raszka B, et al. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry. Pediatr Rheumatol. 2021;19(1):38. doi: 10.1186/s12969-021-00510-8
   PubMedGoogle Scholar
• Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int. 2012;32(2):295–299. doi: 10.1007/s00296-011-2096-3
   PubMed Web of Science ®Google Scholar
• Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis. 2021;81(3):406–415.
   PubMed Web of Science ®Google Scholar
• Polivka L, Diana JS, Soria A, et al. Probable DRESS syndrome induced by IL-1 inhibitors. Orphanet J Rare Dis. 2017;12(1):87. doi: 10.1186/s13023-017-0645-x
   PubMedGoogle Scholar
• Villacis-Nunez DS, Bilcha K, Spraker M, et al. Severe immediate and delayed hypersensitivity reactions to biologics in a toddler with systemic juvenile idiopathic arthritis. J Investig Med High Impact Case Rep. 2022;10:1–6. doi: 10.1177/23247096221077836
   Web of Science ®Google Scholar
• Susanna FN, Pavesio C. A review of ocular adverse events of biological anti-TNF drugs. J Ophthal Inflamm Infect. 2020;10(1):11. doi: 10.1186/s12348-020-00202-6
   PubMed Web of Science ®Google Scholar
• Yokoyama W, Takada K, Miyasaka N, et al. Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. 2014;1:205779. doi: 10.1136/bcr-2014-205779
   Google Scholar
• Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007;66(9):1255–1258.
   PubMed Web of Science ®Google Scholar
• Tauber T, Turetz J, Barash J, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J Am Assoc Pediatr Ophthalmol Strabismus. 2006;10(1):26–29.
   Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248–3252. doi: 10.1002/art.22918
   PubMed Web of Science ®Google Scholar
• Aydin V, Akici A, Isli F, et al. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: a nationwide cohort study. J Clin Pharm Ther. 2019;44(4):553–560. doi: 10.1111/jcpt.12814
   PubMed Web of Science ®Google Scholar